5 completed, 5 unknown, 4 terminated, 2 recruiting. 18 Phase 2, 6 Phase 1, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 18 | Completed 5, Unknown 5, Terminated 4, Recruiting 2, Active not recruiting 1, Withdrawn 1 |
| Phase 1 | 6 | Completed 3, Recruiting 2, Unknown 1 |
| Phase 3 | 2 | Completed 1, Terminated 1 |
Follow Delayed Graft Function: new trials by email Literature Review of Delayed Graft Function trials Research Report on Delayed Graft Function
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| The Effects of Vonoprazan Fumarate on DGF Incidence in DD Kidney Transplant Recipients Vonoprazan fumarate - Delayed Graft Function, Kidney Transplantation | Phase 1 / Phase 2 | Recruiting | First Affiliated Hospital of Chongqing Medical University | 47 | 2025-12-10 | 2025-12-23 |
| ARGX-117 in Deceased Donor Kidney Transplant Recipients at Risk for Delayed Graft Function ARGX-117, Placebo - Delayed Graft Function | Phase 2 | Active not recruiting | argenx | 103 | 2024-02-17 | 2026-10-14 |
| Safety and Efficacy of Treprostinil (Remodulin®) In Reducing Ischemia-Reperfusion Injury During Kidney Transplantation Treprostinil - Ischemia Reperfusion Injury, Delayed Graft Function | Phase 1 / Phase 2 | Recruiting | Rhode Island Hospital | 20 | 2020-11-13 | 2026-04-23 |
| Delayed Renal Allograft Function and Furosemide Treatment Furosemide, Placebo - Delayed Graft Function | Phase 2 | Withdrawn | Loma Linda University | 2016-09-01 | 2016-11-25 | |
| Efficacy, Safety, Tolerability and Pharmacokinetic (PK) Study of GSK1070806 for the Prevention of Delayed Graft Function (DGF) in Adult Subjects After Renal Transplantation GSK1070806, 1) basiliximab 2) mycophenolate mofetil (MMF) OR azathioprine 3) tacrolimus 4) corticosteroids - Kidney Transplantation (Status Post) | Phase 2 | Terminated | GlaxoSmithKline | 7 | 2016-08-27 | 2019-06-26 |
| Effect of BM-MSCs on Early Graft Function Recovery After DCD Kidney Transplant. BM-MSCs, Saline - Kidney Transplantation, Acute Kidney Tubular Necrosis | Phase 1 / Phase 2 | Unknown | First Affiliated Hospital, Sun Yat-Sen University | 120 | 2015-11-01 | 2015-09-30 |
| C1INH Inhibitor Preoperative and Post Kidney Transplant to Prevent DGF & IRI C1 Esterase Inhibitor, Placebo - End Stage Renal Disease, Kidney Failure | Phase 1 / Phase 2 | Completed | Cedars-Sinai Medical Center | 70 | 2014-09-01 | 2018-06-25 |
| Prevention of Delayed Graft Function Using Eculizumab Therapy (PROTECT Study) Eculizumab, Placebo - Delayed Graft Function | Phase 2 / Phase 3 | Completed | Alexion Pharmaceuticals, Inc. | 288 | 2014-08-21 | 2018-12-17 |
| Eculizumab for Prevention of Delayed Graft Function (DGF) in Kidney Transplantation Eculizumab, Normal Saline - Delayed Graft Function, Kidney Transplantation | Phase 2 | Terminated | Heeger, Peter, M.D. | 21 | 2013-08-01 | 2018-02-27 |
| Early Conversion From CNI to Belatacept in Renal Transplant Recipients With Delayed and Slow Graft Function Belatacept, Calcineurin Inhibitor - Delayed Graft Function, Kidney Transplant | Phase 2 | Unknown | Nair, Vinay, D.O. | 90 | 2013-06-01 | 2017-01-30 |
| A Pilot Study Comparing the Safety and Efficacy of Everolimus With Other Medicines in Recipients of ECD/DCD Kidneys Everolimus, Tacrolimus, Mycophenolate mofetil (MMF/MPA) - Delayed Graft Function | Phase 2 / Phase 3 | Terminated | Matthew Cooper | 25 | 2013-06-01 | 2019-04-26 |
| Placebo-Controlled Study to Evaluate the Safety and Efficacy of OPN-305 in Preventing Delayed Renal Graft Function OPN-305, Placebo - Delayed Graft Function | Phase 2 | Completed | Opsona Therapeutics Ltd. | 252 | 2012-10-01 | 2017-02-16 |
| A Study of the Activity of Eculizumab for Prevention of Delayed Graft Function In Deceased Donor Kidney Transplant Eculizumab, Placebo - Delayed Function of Renal Transplant | Phase 2 | Terminated | Schroppel, Bernd, M.D. | 8 | 2011-12-01 | 2019-05-06 |
| Study on Delayed Graft Function Using Paired Kidneys BB3, Normal Saline - Delayed Graft Function | Phase 2 | Unknown | Angion Biomedica Corp | 12 | 2011-08-01 | 2016-02-22 |
| Study to Improve Renal Function After Kidney Transplantation BB3 - Delayed Graft Function | Phase 2 | Unknown | Angion Biomedica Corp | 30 | 2010-02-01 | 2015-05-05 |
| I5NP for Prophylaxis of Delayed Graft Function in Kidney Transplantation I5NP, Saline - Delayed Graft Function, Other Complication of Kidney Transplant | Phase 1 / Phase 2 | Completed | Quark Pharmaceuticals | 374 | 2008-12-01 | 2014-09-18 |
| YSPSL for Prevention of Delayed Graft Function in Cadaveric Liver Transplantation YSPSL, Placebo - Liver Diseases | Phase 2 | Unknown | Y's Therapeutics, Inc. | 12 | 2007-03-01 | 2008-01-29 |
| YSPSL for Prevention of Delayed Graft Function Part B YSPSL, placebo - Kidney Diseases | Phase 1 / Phase 2 | Completed | Y's Therapeutics, Inc. | 60 | 2006-05-01 | 2008-01-29 |
Renal Insufficiency (2) · Reperfusion Injury (2) · Deafness, Autosomal Recessive 39 (1) · Kidney Diseases (1) · Kidney Failure, Chronic (1) · Kidney Tubular Necrosis, Acute (1) · Liver Diseases (1) · Renal Insufficiency, Chronic (1)
Pathologic Processes (18) · Pathological Conditions, Signs and Symptoms (18) · Female Urogenital Diseases (4) · Female Urogenital Diseases and Pregnancy Complications (4) · Male Urogenital Diseases (4) · Urogenital Diseases (4) · Urologic Diseases (4) · Kidney Diseases (3) · Cardiovascular Diseases (2) · Postoperative Complications (2) · Vascular Diseases (2) · Acute Kidney Injury (1) · Chronic Disease (1) · Digestive System Diseases (1) · Disease Attributes (1)
Sodium Chloride (4) · Saline Solution (3) · eculizumab (3) · Mycophenolic Acid (2) · Tacrolimus (2) · Abatacept (1) · Adrenal Cortex Hormones (1) · Calcineurin Inhibitors (1) · Complement C1 Inhibitor Protein (1) · Cyclosporine (1) · Everolimus (1) · Furosemide (1) · GSK1070806 (1) · University of Wisconsin-lactobionate solution (1) · tomaralimab (1)
Angion Biomedica Corp (2) · Y's Therapeutics, Inc. (2) · Alexion Pharmaceuticals, Inc. (1) · Cedars-Sinai Medical Center (1) · First Affiliated Hospital of Chongqing Medical University (1) · First Affiliated Hospital, Sun Yat-Sen University (1) · GlaxoSmithKline (1) · Heeger, Peter, M.D. (1) · Loma Linda University (1) · Matthew Cooper (1) · Nair, Vinay, D.O. (1) · Opsona Therapeutics Ltd. (1) · Quark Pharmaceuticals (1) · Rhode Island Hospital (1) · Schroppel, Bernd, M.D. (1)
United States (14) · Spain (6) · France (4) · Canada (3) · Germany (3) · United Kingdom (3) · Australia (2) · Austria (2) · Belgium (2) · Brazil (2) · China (2) · Czechia (2) · Italy (2) · Netherlands (2) · Poland (1)
Stefan Hemmerich, PhD (2) · Amir Abdipour, MD (1) · Ashley Vo, PharmD (1) · Bernd Schroppel, MD (1) · Changxi Wang, M.D., Ph.D (1) · Matthew Cooper (1) · Peter S Heeger, MD (1) · Robert M Miller, FRCS MBBS (1) · Shai Erlich, Ph.D. (1) · Stanley C Jordan, MD (1) · Vinay Nair, D.O. (1) · Weizhong Cai, PhD (1)
PMID 20573162, PMID 21114535, PMID 33684160, PMID 42763038
2015 (1), R44DK066654 (1), R44DK078455 (1)